Get the Stockscreener App
5.09
0.78%
-0.04
After Hours:
5.06
-0.03
-0.59%
Xeris Biopharma Holdings Inc stock is traded at $5.09, with a volume of 2.15M.
It is down -0.78% in the last 24 hours and up +8.99% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$5.13
Open:
$5.13
24h Volume:
2.15M
Relative Volume:
1.04
Market Cap:
$796.00M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-12.12
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
-1.55%
1M Performance:
+8.99%
6M Performance:
+42.98%
1Y Performance:
+105.24%
1-Day Range:
$5.07
$5.34
1-Week Range:
$4.9447
$5.34
52-Week Range:
$2.095
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.09 | 821.60M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
How strong is Xeris Biopharma Holdings Inc. company’s balance sheetStock Strategy Trend Scanner For Every Investor - jammulinksnews.com
What makes Xeris Biopharma Holdings Inc. stock price move sharplyProfitable Trading Blueprint with Entry Zones - Newser
AI Trend Models Suggest Bounce for Xeris Biopharma Holdings Inc.Conservative Long Term Growth Plans Under Review - metal.it
Why Xeris Biopharma Holdings Inc. stock attracts strong analyst attentionFundamental + Technical Hybrid Stock Tips Shared - metal.it
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a favorite amongst institutional investors who own 54% - Yahoo.co
How did XERS's Q4 earnings surprise impact investor confidence? - AInvest
Xeris Biopharma Holdings Inc. Stock Support and Resistance Levels You Should KnowLong-Term Investment Strategy Impact Analysis - Newser
Is Xeris Biopharma Holdings Inc. Stock a Good Fit for Conservative InvestorsFree Stock Market Watch With Alerts - Newser
Can momentum traders help lift Xeris Biopharma Holdings Inc.Daily Technical Forecast for Quick Gains - Newser
Xeris Biopharma Holdings Inc. stock daily chart insightsSafe Investment Ideas with Growth Upside - Newser
Trend Dashboard Flags Xeris Biopharma Holdings Inc. As Potential Swing TradeBreakout Momentum Picks With Protection Outlined - metal.it
What are Xeris Biopharma Holdings Inc. company’s key revenue driversBreakout Stocks Opportunities Backed By Experts - jammulinksnews.com
Is it the right time to buy Xeris Biopharma Holdings Inc. stockAchieve superior capital gains with smart trades - jammulinksnews.com
What are the latest earnings results for Xeris Biopharma Holdings Inc.Accelerated earnings growth - jammulinksnews.com
Is Xeris Biopharma Holdings Inc. a growth stock or a value stockSuperior capital gains - jammulinksnews.com
New York State Common Retirement Fund Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Cwm LLC Increases Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
What analysts say about Xeris Biopharma Holdings Inc. stockTremendous return rates - PrintWeekIndia
Is Xeris Biopharma Holdings Inc. a good long term investmentDouble or triple returns - PrintWeekIndia
Will Xeris Biopharma Holdings Inc. stock split in the near futureGame-changing capital returns - jammulinksnews.com
Xeris Biopharma Holdings Inc. Stock Analysis and ForecastFree Investment Case Studies - PrintWeekIndia
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What drives Xeris Biopharma Holdings Inc. stock pricePowerful profit generation - jammulinksnews.com
How Xeris Biopharma Holdings Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
Xponance Inc. Invests $57,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):